Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask

Document Type : Original Article (s)

Authors

1 Professor, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences AND Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences AND Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, AND Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Department of Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Student of Pharmacy, School of Pharmacy and Pharmaceutical Sciences AND Isfahan Pharmaceutical Sciences Research Center AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

6 Specialist in Infectious Diseases, Isfahan Province Health Center, Isfahan University of Medical Sciences, Isfahan, Iran

7 Isfahan Province Health Center, Isfahan University of Medical Sciences, Isfahan Iran

Abstract

Background: Pentavalent antimony compounds are the main treatment for cutaneous leishmaniasis. Usually, this drug is injected into the lesion for acute treatment, which is very painful and results in low patient compliance. In this study we sought to prepare a topical form of this drug, which is not available in the market.Methods: In this study glucantime gel mask was prepared by using polyvinyl alcohol (PVA), sodium carboxymethylcellulose, and hydroxypropyl methylcellulose as the base polymer and glycerin as the plasticizer. The gel mask was optimized, evaluated for physicochemical properties, and examined on 40 patients with cutaneous leishmaniasis. Patients were randomly divided into control and test groups. All patients received weekly intralesional injection of meglumine antimoniate as routine care. The prepared gel mask was applied twice a day in the test group, and the control group received the placebo gel mask.Findings: PVA was used because its consistency value is better and it causes the rapid release of drug from the base. The optimized formulation showed good physicochemical property. 25 males and 15 females participated in the clinical trial with the mean age of 28.2 years for 6 weeks. There were no significant differences between the two groups in terms of gender, age, and duration of disease. In the test group, 15 patients achieved complete cure at the end of week 6, 2 moderate cure, and 1 mild cure, and 1 patient did not have an acceptable cure. In the control group, 13 patients achieved complete cure and 5 moderate cure, 2 showed no improvement, and in 1 patient the lesion got worse.Conclusion: The gel mask reduces the weekly meglumine antimoniate requirement. This reduction shows the appropriate penetration of the drug from the gel into the lesion.

Keywords

References

  1. Ershadi MR, Zahraei-Ramazani AR, Akhavan AA, Jalali-Zand AR, Abdoli H, Nadim A. Rodent control operations against zoonotic cutaneous leishmaniasis in rural Iran. Ann Saudi Med 2005; 25(4): 309-12.
  2. Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol 2007; 25(2): 203-11.
  3. Nilforoushzadeh M, Sadeghian G. Cutaneous leishmaniosis. 1st ed. Isfahan, Iran: Isfahan University of Medical Sciences; 2002. [In Persian].
  4. Lewis DJ. The biology of Phlebotomidae in relation to leishmaniasis. Annu Rev Entomol 1974; 19: 363-84.
  5. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; (4): CD005067.
  6. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009; 3(2): e381.
  7. Larbi EB, al-Khawajah A, al-Gindan Y, Jain S, Abahusain A, al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg 1995; 52(2): 166-8.
  8. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94(3): 319-22.
  9. Zeina B, Banfield C, al-Assad S. Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin Exp Dermatol 1997; 22(5): 244-5.
  10. Punitha S, Girish Y. Polymers in muco adhesive buccal drug delivery system -Areview. Int J Res Pharm Sci 2010; 1(2): 170-86.
  11. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 2005; 57(11): 1666-91.
  12. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53(6): 648-51.
  13. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31(5): 634-7.
  14. Clive S, Leonard RC. Miltefosine in recurrent cutaneous breast cancer. Lancet 1997; 349(9052): 621-2.
  15. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93(1): 85-90.
  16. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179(6): 1485-94.
  17. Ilg T, Fuchs M, Gnau V, Wolfram M, Harbecke D, Overath P. Distribution of parasite cysteine proteinases in lesions of mice infected with Leishmania mexicana amastigotes. Mol Biochem Parasitol 1994; 67(2): 193-203.
  18. El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1984; 26(5): 745-51.
Journal of Isfahan Medical School
Volume 31, Issue 231 - Serial Number 231
March and April 2013
Pages 389-399

Files

History

  • Receive Date: 04 March 2013
  • Revise Date: 03 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics